Evidence map›Paper›PMID 41012159›Full record

ArticleVaccines2025

Presence of Vaccine-Induced Antibodies Against

Katharina Gesa Schmitt, Michèle Bergmann, Hans van der Linden, Ahmed A Ahmed, Reinhard K Straubinger, Yury Zablotski, Katrin Hartmann

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. FiveMicroorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katharina Gesa SchmittLMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich, Veterinärstrasse 13, 80539 Munich, Germany.
Michèle BergmannLMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich, Veterinärstrasse 13, 80539 Munich, Germany.
Hans van der LindenExpertise Centre for Reference and Research on Leptospirosis, WOAH Reference Laboratory for Leptospirosis, UMC, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands.ORCID 0009-0006-8656-5839
Ahmed A AhmedExpertise Centre for Reference and Research on Leptospirosis, WOAH Reference Laboratory for Leptospirosis, UMC, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-6169-5323
Reinhard K StraubingerInstitute of Bacteriology and Mycology, Department of Veterinary Sciences, Faculty of Veterinary Medicine, LMU Munich, Sonnenstrasse 24, 85764 Oberschleissheim, Germany.ORCID 0000-0001-8382-7182
Yury ZablotskiLMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich, Veterinärstrasse 13, 80539 Munich, Germany.ORCID 0000-0001-6928-4089
Katrin HartmannLMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich, Veterinärstrasse 13, 80539 Munich, Germany.ORCID 0000-0002-5256-863X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeptospirosis is a potentially fatal infectious disease. Therefore, annual revaccination of dogs is recommended, but this can lead to diagnostic interference due to vaccine-induced antibodies. This study determined the prevalence of

methodsAntibodies were measured with a microscopic agglutination test against 12 serovars before (week 0) and 2, 4, 12, 26, and 52 weeks after revaccination. Logistic regression analysis was performed to determine the presence of pre-revaccination antibodies. Mixed-effect logistic regression analyses and chi-squared tests were used to compare differences between antibodies against vaccine serovars and between vaccine and non-vaccine serovars at different time points.

resultsOverall, 63/97 dogs (64.9%) had antibodies against vaccine serovars before revaccination. During the study period, antibodies against ≥1 vaccine serovars were detected in all 97 dogs (100.0%). The highest likelihood of detectable antibodies was present in weeks 2 and 4, but 71/97 dogs (73.2%) had antibodies persisting 52 weeks after revaccination. Of 97 dogs, 75 dogs (78.4%) even had antibodies against ≥1 non-vaccine serovars. Among those, 19/75 (25.0%) had a fourfold titre increase.

conclusionsThese findings suggest that high levels of antibody titres against

Indexed as

4-serovar vaccineimmune responseimmunizationLeptospira spp.leptospirosisMATpost-vaccination antibodiesvaccination

Identifiers

PMID41012159
PMCPMC12474255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.